Alefacept Mechanism of Action in Psoriasis

Completed · Phase 2

Conditions studied: Psoriasis

In brief

To determine the mechanism of action of alefacept in patients with psoriasis.

Key facts

Study ID

NCT00150982

Run by

University of Medicine and Dentistry of New Jersey

People needed

9

Starts

2003-09-01

Expected to finish

2005-02-01

Last updated by the study team

2008-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Alefacept is indicated for the treatment of adult patients (18 years or older) with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. Patients must have at least one plaque of least 2.5 cm in diameter (for biopsies).

You may not qualify if…

• CD4 < 400/ml
• WBC less than lower level of normal for the reporting laboratory
• < 5% Body Surface Area involved with psoriasis
• Serious infection e.g., latent or active tuberculosis
• History of AIDS or Hepatitis B,C, all internal cancers, lymphoma, untreated cutaneous basal or squamous cell carcinoma
• Systemic anti-psoriasis medications and phototherapy within 28 days of the first dose of Alefacept
• Topical anti-psoriasis medications within 14 days of the first dose of Alefacept, except for moisturizers, tar shampoos (exception, Elidel is permitted to be applied on the face, groin and axillae areas. These areas are not biopsied.)
• Inability to understand consent form or comply with study requirements
• Pregnancy or lactation
• Concurrent medical illness that would make participation in this clinical trial ill-advised
• Any contraindications to using alefacept

Where it is running

• UMDNJ Clinical Research Center — New Brunswick, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.